ଡିଗକ୍ସିନ

ଡିଗକ୍ସିନ
Clinical data
Pronunciation	/dɪˈdʒɒksɪn/, with a soft gee
Trade names	Lanoxin, others
AHFS/Drugs.com	monograph
MedlinePlus	a682301
Pregnancy; category	AU: A ; US: C (Risk not ruled out) ; ;
Routes of; administration	by mouth, intravenous
ATC code	C01AA05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	60 to 80% (by mouth)
Protein binding	25%
Metabolism	liver (16%)
Elimination half-life	36 to 48 hours ; (normal kidney function); 3.5 to 5 days ; (impaired kidney function)
Excretion	kidney
Identifiers
	IUPAC name 4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one;
CAS Number	20830-75-5 ;
PubChem CID	2724385;
IUPHAR/BPS	4726;
DrugBank	DB00390 ;
ChemSpider	2006532 ;
UNII	73K4184T59;
KEGG	D00298 ;
ChEBI	CHEBI:4551 ;
ChEMBL	CHEMBL1751 ;
ECHA InfoCard	100.040.047
Chemical and physical data
Formula	C41H64O14
Molar mass	780.949 g/mol
3D model (JSmol)	Interactive image;
Melting point	249.3 °C (480.7 °F)
Solubility in water	0.0648 mg/mL (20 °C)
	SMILES O=C\1OC/C(=C/1)[C@H]2CC[C@@]8(O)[C@]2(C)[C@H](O)C[C@H]7[C@H]8CC[C@H]6[C@]7(C)CC[C@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@@H](O)C3)C)[C@@H](O)C4)C)[C@@H](O)C5)C6;
	InChI InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1 ; Key:LTMHDMANZUZIPE-PUGKRICDSA-N ;
(verify)

ଡିଗକ୍ସିନ (ଇଂରାଜୀ ଭାଷାରେ Digoxin, ବିକ୍ରୟ ନାମ ଲାନୋକ୍ସିନ, ଏକ ଔଷଧ ଯାହା ଅନେକ ପ୍ରକାରର ହୃଦ୍‌ରୋଗର ଚିକିତ୍ସା ନିମନ୍ତେ ଦିଆଯାଏ । ଅଧିକାଂଶ ସମୟରେ ଏହା ଆଟ୍ରିଆଲ ଫିବ୍ରିଲେସନ, ଆଟ୍ରିଆଲ ଫ୍ଲଟର (atrial flutter) ଓ ହୃଦ୍‌ପାତ ରୋଗମାନଙ୍କରେ ଦିଆଯାଏ । ଡିଗକ୍ସିନ ପାଟିରେ ବା ଶିରାଭ୍ୟନ୍ତରରେ (injection into a vein) ଦିଆଯାଏ ।^[୨]

ଡିଗକ୍ସିନର ମାତ୍ରାଧିକ ହେଲେ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସ୍ତନବୃଦ୍ଧି ବା ଗାଇନେକୋମାସ୍ଟିଆ (breast enlargement) ହୋଇପାରେ ।^[୨]^[୩] ଅନ୍ୟାନ୍ୟ ପ୍ରତିକ୍ରିୟା ମଧ୍ୟରେ ଅରୁଚି, ଅଇ, ଦୃଷ୍ଟି ସମସ୍ୟା, ଦ୍ୱନ୍ଦ୍ୱ ଓ ଅନିୟମିତ ହୃତ୍‌ ସ୍ପନ୍ଦ‌ନ ହୋଇପାରେ । ସିନିଅର ସିଟିଜେନମାନଙ୍କର ଅଧିକ ଯତ୍ନ ଆବଶ୍ୟକ ହୁଏ ବିଶେଷତଃ ଯଦି ବୃକ୍‌କ ସମସ୍ୟା (kidney function) ଥାଏ ।^[୩] ଗର୍ଭାବସ୍ଥାରେ ଏହାର ପ୍ରଭାବ ସ୍ପଷ୍ଟ ହୋଇନାହିଁ ।^[୪] ଏହା କାର୍ଡ଼ିଆକ ଗ୍ଲାଇକୋସାଇଡ (cardiac glycoside) ଶ୍ରେଣୀର ଏହ ଔଷଧ ।^[୨]

ଡିଗକ୍ସିନ ପ୍ରଥମେ ଫକ୍ସଗ୍ଲୋଭ ଗଛ foxglove ବା ଡିଜିଟାଲିସ ଲାନାଟାରୁ (Digitalis lanata)ରୁ ପୃଥକ କରାଯାଇଥିଲା ସନ ୧୯୩୦ ମସିହାରେ ।^[୫]^[୬] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ (World Health Organization's List of Essential Medicines) ଅଛି ଯାହା ମୌଳିକ ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ (health system) ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ ।^[୭] ବିକାଶଶୀଳ ଦେଶମାନଙ୍କରେ (developing world) ଏହି ଔଷଧର ଏକ ମାସ ଡୋଜର କ୍ରୟ ମୂଲ୍ୟ ୦.୨୧ରୁ ୬.୬ ଆମେରିକୀୟ ଡଲାର ।^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହାର ଏକ ମାସ ଡୋଜର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୨୫ ଆମେରିକୀୟ ଡଲାର ।^[୯]

ଆଧାର

↑ OED
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Digoxin". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
↑ ^୩.୦ ^୩.୧ WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 270. ISBN 9789241547659. Retrieved 8 December 2016.
↑ "Digoxin Use During Pregnancy | Drugs.com". www.drugs.com. Retrieved 14 December 2016.
↑ Cartwright, Anthony C. (2016). The British Pharmacopoeia, 1864 to 2014: Medicines, International Standards and the State (in ଇଂରାଜୀ). Routledge. p. 183. ISBN 9781317039792.
↑ Hollman, A (6 April 1996). "Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata". BMJ (Clinical research ed.). 312 (7035): 912. doi:10.1136/bmj.312.7035.912. PMC 2350584. PMID 8611904.
↑ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
↑ "Digoxin". International Drug Price Indicator Guide. Retrieved 8 December 2016.^{[permanent dead link]}
↑ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. X. ISBN 9781284057560.

[1] OED

[AHFS2016-2] ୨.୦ ^୨.୧ ^୨.୨ "Digoxin". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.

[WHO2008-3] ୩.୦ ^୩.୧ WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 270. ISBN 9789241547659. Retrieved 8 December 2016.

[4] "Digoxin Use During Pregnancy | Drugs.com". www.drugs.com. Retrieved 14 December 2016.

[5] Cartwright, Anthony C. (2016). The British Pharmacopoeia, 1864 to 2014: Medicines, International Standards and the State (in ଇଂରାଜୀ). Routledge. p. 183. ISBN 9781317039792.

[6] Hollman, A (6 April 1996). "Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata". BMJ (Clinical research ed.). 312 (7035): 912. doi:10.1136/bmj.312.7035.912. PMC 2350584. PMID 8611904.

[WHO19th-7] "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.

[ERC2014-8] "Digoxin". International Drug Price Indicator Guide. Retrieved 8 December 2016.^{[permanent dead link]}

[Ric2015-9] Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. X. ISBN 9781284057560.

[୨]

[୧]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

Clinical data


Pronunciation	/dɪˈdʒɒksɪn/, with a soft gee^[୧]
Trade names	Lanoxin, others
AHFS/Drugs.com	monograph
MedlinePlus	a682301
Pregnancy category	AU: A US: C (Risk not ruled out)
Routes of administration	by mouth, intravenous
ATC code	C01AA05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	60 to 80% (by mouth)
Protein binding	25%
Metabolism	liver (16%)
Elimination half-life	36 to 48 hours (normal kidney function) 3.5 to 5 days (impaired kidney function)
Excretion	kidney
Identifiers
IUPAC name 4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
CAS Number	20830-75-5^Y
PubChem CID	2724385
IUPHAR/BPS	4726
DrugBank	DB00390^Y
ChemSpider	2006532^Y
UNII	73K4184T59
KEGG	D00298^Y
ChEBI	CHEBI:4551^Y
ChEMBL	CHEMBL1751^Y
ECHA InfoCard	100.040.047
Chemical and physical data
Formula	C₄₁H₆₄O₁₄
Molar mass	780.949 g/mol
3D model (JSmol)	Interactive image
Melting point	249.3 °C (480.7 °F)
Solubility in water	0.0648 mg/mL (20 °C)
SMILES O=C\1OC/C(=C/1)[C@H]2CC[C@@]8(O)[C@]2(C)[C@H](O)C[C@H]7[C@H]8CC[C@H]6[C@]7(C)CC[C@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@@H](O)C3)C)[C@@H](O)C4)C)[C@@H](O)C5)C6
InChI InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1^Y Key:LTMHDMANZUZIPE-PUGKRICDSA-N^Y
(verify)